On 3 August, Eli Lilly confirmed it will let a limited group of patients apply for access to retatrutide — an obesity drug that has not been approved by any regulator — ahead of a filing the company has said will come in the first quarter of 2027. Eligibility is deliberately narrow: adults with obesity that has not responded to the highest tolerated dose of an approved therapy, who carry at least two serious obesity-related complications, and who cannot enrol in a trial.
Read narrowly, this is a routine expanded-access programme. Read against everything else happening in the peptide economy this summer, it is something more interesting: a signal that demand for these molecules has outrun the regulatory machinery designed to meter them out, and that the companies, the agencies and the gray market are all now improvising in public.
Six weeks earlier, reporting revealed that a single 79-year-old patient had already been granted compassionate-use access to the same compound. Doctors read the story and started asking for the same thing for their own patients. The programme announced this week is, in effect, the institutional answer to a queue that formed on its own.
This paper sets out what the data actually supports, where the excitement is justified, where the controversy is legitimate rather than performative, and which parts of the opportunity look mispriced from where we sit.
One in nine American adults is now on a GLP-1
The adoption curve for this drug class has almost no precedent in outpatient medicine. Gallup's National Health and Well-Being Index puts current GLP-1 use for weight loss at 11% of US adults in mid-2026, up from 8% in 2025 and 3% in 2024. Fifteen percent say they have used one at some point. Ninety-one percent of Americans now know what these drugs do.
The population-level signal is arriving alongside it. Self-reported adult obesity prevalence in the same survey series has fallen from 39.9% in 2022 to 36.4% in 2026 — four consecutive years of decline, concurrent with the prescribing surge. Causation is not established by a correlation of this kind, but the direction is consistent with the trial data, and no competing explanation has been offered that fits as well.
Retatrutide moves the ceiling into surgical territory
Retatrutide is a triple agonist: it engages the GLP-1 and GIP receptors like tirzepatide, and adds glucagon. In the TRIUMPH-4 trial, the highest evaluated dose produced an average 28.7% reduction in body weight over 68 weeks, alongside improvement in knee osteoarthritis pain. Lilly now has positive Phase 3 results across five trials and has guided to a Q1 2027 filing.
The number matters because of where it lands. Roux-en-Y gastric bypass and sleeve gastrectomy typically deliver 25–35% total body weight loss. A weekly injection is now inside that band. That does not make the two interchangeable — surgery is a one-time intervention with durable anatomical effects, and the drug's effect persists only while the patient keeps taking it — but it changes the conversation for every payer, every surgeon and every patient who was weighing an operation.
The science kept improving through 2026. The revenue forecasts did the opposite. That divergence is the single most important thing happening in this sector.
Better drugs, smaller market
Through 2024 and 2025, sell-side estimates for the obesity drug market marched upward: roughly $100bn by 2030 from Goldman Sachs, $150bn by 2033 from BMO, $158bn by 2032 from Leerink. In February 2026, Novo Nordisk guided to a 2026 sales decline of 5–13% against a consensus expectation of about 2%, and the sector repriced in a day. Analysts began pushing out peak-sales timelines, with some now placing the 2030 market closer to $80–105bn.
Nothing clinical caused that. The cause was price. Cash-pay prices in the US fell hard through late 2025 and 2026 — Wegovy and Ozempic to $349 a month direct-to-consumer, Zepbound starting at $299, and a federal agreement capping Medicare beneficiary cost at $50 a month for Zepbound and the oral, subject to approval. Volume is exploding and unit economics are compressing at the same time.
For investors this is the defining structural fact of the category: this is now a volume business with consumer-goods pricing dynamics, not a specialty-pharma business with specialty-pharma margins. The winners will be decided by manufacturing cost per dose, distribution reach and adherence — not by another two points of weight loss.
Nobody agrees how big "peptides" even is
Anyone doing diligence in this space will collide with a data problem quickly. Published estimates for the 2026 global peptide therapeutics market range from roughly $52bn to $164bn — a threefold spread across reputable research houses, in the same year.
The spread is not sloppiness. It is definitional. Some houses count only therapeutic peptide drug revenue; others fold in insulin analogues, peptide-adjacent biologics, contract manufacturing, or the full GLP-1 franchise including diabetes indications. A three-times variance in the denominator makes almost any top-down TAM claim in this sector unusable without reading the methodology.
Our working position: ignore the headline TAM entirely. Underwrite from unit economics — doses manufactured, cost per dose, patients retained past month six — and treat all published market sizing as directional colour only.
The gray market got a vote
Alongside the approved franchises sits a parallel economy of peptides that are neither approved drugs nor lawful dietary supplements: BPC-157, TB-500, MOTS-c, Semax, Epitalon and others, marketed for tissue repair, longevity, cognition and recovery. They are sold online as "research chemicals, not for human consumption" — a disclaimer that everyone involved understands to be fiction. Researchers writing in JAMA counted more than 130,000 Instagram posts and over 230 million TikTok views on synthetic peptides.
On 23–24 July 2026, the FDA's Pharmacy Compounding Advisory Committee took up seven of these substances for possible inclusion on the 503A Bulks List — the list that determines what traditional compounding pharmacies may legally use. FDA's own reviewers recommended against all seven, citing weak chemical characterisation, unresolved immunogenicity risk, undocumented manufacturing quality and a near-absence of modern human efficacy data. One FDA official noted a more basic problem: for several of these substances, the agency cannot reliably define what the thing being nominated actually is, because products sold under the same name vary in composition.
The committee voted for six of the seven anyway, by narrow margins. BPC-157 passed 8–6 with one abstention. Emideltide (DSIP) was the single rejection, 7–6 with one abstention.
| Substance | FDA staff view | Committee | Note |
|---|---|---|---|
| BPC-157 | Against | For — 8:6:1 | Reviewed for ulcerative colitis; mostly rodent data |
| KPV | Against | For — narrow | Inflammatory conditions |
| TB-500 | Against | For — narrow | Prohibited under WADA |
| MOTS-c | Against | For — narrow | Prohibited under WADA |
| Semax | Against | For — narrow | Approved in Russia under a different standard |
| Epitalon | Against | For — narrow | Marketed for longevity; legacy evidence base |
| Emideltide (DSIP) | Against | Against — 7:6:1 | Only rejection of the two days |
Three things about this vote are widely misreported, and they matter for anyone underwriting a peptide clinic, telehealth platform or compounding pharmacy.
It is not an approval. A PCAC recommendation is advisory. Inclusion on the 503A Bulks List requires FDA acceptance plus proposed and final rulemaking, and formal sign-off at HHS. As of today, none of the seven may lawfully be compounded, and none is an approved drug for any indication.
The list it would join is tiny. The codified 503A bulks list currently contains six substances, five of them topical. Adding six peptides would more than double it — which is why the vote drew the coverage it did.
The committee's composition was itself contested. Reporting noted that the reconstituted panel included increased representation from clinicians and businesses involved in prescribing, producing or promoting peptides, and that several "yes" votes came from members affiliated with telehealth companies positioned to benefit. Several members framed their vote pragmatically rather than scientifically: a regulated compounding channel, they argued, is better than the alternative patients are already using.
That argument — harm reduction against an ungovernable gray market — is the most honest case for the vote and the most dangerous precedent in it.
What the safety record actually shows
The approved GLP-1s have a well-characterised profile dominated by gastrointestinal effects, with large cardiovascular and metabolic benefits demonstrated in outcome trials. The risk concentrates elsewhere: in what patients take instead.
Roughly one in five current GLP-1 users reports taking a compounded or custom-mixed version that is not FDA-approved. That channel carries a distinct failure mode. Compounded product arrives in vials rather than pre-filled pens, and dosing measured in "units" rather than millilitres has produced ten-fold overdoses in poison-centre data. National Poison Data System analysis of more than 10,000 GLP-1 exposures found call volume rising sharply post-2021, driven by therapeutic errors: daily instead of weekly dosing, skipped titration, wrong dose. Poison centres have also begun logging exposures to retatrutide bought online as a research chemical — the same compound Lilly is now rationing through a formal programme.
Additional documented issues: unapproved salt forms such as semaglutide sodium; additive cocktails with B12 or niacinamide that have no weight-loss rationale, where a 2026 study found tirzepatide and B12 can chemically bond into a molecule absent from the approved product; fraudulent labels naming compounding pharmacies that do not exist; and counterfeit semaglutide, which in European pharmacovigilance data is associated with more serious case reports and a higher reporting probability for hypoglycaemia and drug ineffectiveness.
On 30 April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, which would close the last broad legal route to compounded GLP-1s, and it has issued warning letters to dozens of companies over misleading claims. The regulatory direction on GLP-1 copies is tightening at precisely the moment the direction on wellness peptides loosened. That asymmetry is worth sitting with.
The supplement category is where the next fight happens
Below the pharmaceutical layer sits a consumer peptide market valued at roughly $4.1bn in 2025 and projected at $11.2bn by 2035 — cosmetic peptides, collagen and elastin actives, oral peptide supplements, and the harder-to-classify recovery and longevity compounds now stocked by major e-commerce platforms.
This is where regulatory arbitrage is most acute. A compound like BPC-157 cannot lawfully be sold as a dietary supplement in the US, but the enforcement gap between "cannot be sold" and "is not being sold" is wide, and consumers routinely stack these products with conventional supplements. Legal scholars and clinicians in multiple jurisdictions are now calling for tighter surveillance.
For operators, the practical read is that ingredient-level compliance risk is about to become the dominant diligence question in consumer health — not marketing claims, not channel strategy. A brand's entire enterprise value can sit on whether one ingredient is on the right list in eighteen months.
The highest need, the smallest market
Egypt has the highest adult obesity prevalence in the Arab States — 44.3% in 2022, against a regional average of 32.1% and a global average of 15.8%. Among Egyptian adult women, WHO-modelled prevalence reaches 44.7%; national screening data put obesity across all adults near 40%, with type 2 diabetes affecting roughly one in five adults.
The Middle East and Africa accounted for 1.4% of global GLP-1 receptor agonist revenue in 2025.
Adult obesity prevalence, Egypt, 2022 — highest in the Arab States
MEA share of global GLP-1 receptor agonist revenue, 2025
That gap is not a market inefficiency waiting to be arbitraged by importing US commercial models. Injectable branded therapy at Western cash prices is unreachable for the overwhelming majority of Egyptian households, and public reimbursement for chronic weight management does not exist at scale. Lilly's own framing — that only 1–2% of people who could benefit globally currently use these drugs — describes the opportunity honestly and the difficulty not at all.
Where we think the region actually opens: orals, not injectables. Small-molecule oral GLP-1s remove the cold chain, the pen device and much of the manufacturing constraint. Early US data on oral entrants showed roughly two-thirds of volume coming from patients new to GLP-1 therapy rather than switching — evidence that convenience and price expand the market rather than reallocating it. Add local and regional manufacturing partnerships, generic semaglutide entry as patents lapse across emerging markets, and pharmacist-led rather than specialist-led care models, and a plausible MENA pathway exists that looks nothing like the American one.
The counterweight is enforcement capacity. Where legitimate access is thin and demand is enormous, counterfeit and diverted product fills the space. Every regional market that has run ahead of its regulatory infrastructure on these drugs has generated the same set of problems.
What we are watching
- Whether HHS ratifies the July peptide recommendationsRulemaking, not the committee vote, is the event. Anyone building a business on the assumption that compounded BPC-157 is imminent is trading on a headline, not a rule.
- The 503B exclusion for semaglutide and tirzepatideIf finalised, the compounded GLP-1 channel that ~19% of users rely on largely closes. Those patients go somewhere. Where they go is the story of 2027.
- Cost per dose, disclosed or inferredIn a market repricing toward $299–$349 a month, manufacturing efficiency is the moat. Oral small molecules are structurally advantaged over synthesised peptides on this axis.
- Twelve-month persistence, not twelve-week weight lossReal-world effectiveness depends on continuity of care and correct titration. Retention data will separate durable businesses from acquisition-funded ones.
- Retatrutide's Q1 2027 filing and its priceA near-surgical outcome from a weekly injection reframes bariatric surgery economics, payer policy and the entire cost-effectiveness literature. The launch price will tell us whether Lilly reads this as a premium product or a volume one.
Our summary position: the clinical thesis for incretin peptides has strengthened materially and continues to. The equity thesis has weakened, because price is falling faster than volume is rising. And the wellness-peptide thesis remains, in our view, uninvestable at the ingredient level until rulemaking settles — not because the compounds are necessarily worthless, but because nobody, including the FDA, can yet reliably say what is in the vial.